Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Coya Therapeutics Inc. is active in the Chemistry & Materials technology area. The portfolio currently has 2 pending office actions. These actions are split between 2 distinct examiners and 2 distinct art units, showing a diversified examination process for the company's material-related filings. This distribution indicates that the company's applications are being reviewed by different specialized sections of the USPTO.
The busiest examiner for the portfolio is HYUN, PAUL SANG HWA, who is responsible for 1 busiest examiner pending action. This represents a portion of the 2 pending office actions currently on file. The involvement of 2 distinct art units suggests that the company's technology is being evaluated under different specialized criteria. For practitioners, this requires a prosecution strategy that can adapt to the specific requirements of each art unit while managing the interactions with the 2 distinct examiners involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HYUN, PAUL SANG HWA | 1 | 69.8% | +36.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692235 | Serum Immune-Based Biomarkers for Use in ALS Therapy | HYUN, PAUL SANG HWA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692235 | Serum Immune-Based Biomarkers for Use in ALS Therapy | HYUN, PAUL SANG HWA | — |
| Art Unit | Apps |
|---|---|
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692235 | Serum Immune-Based Biomarkers for Use in ALS Therapy | HYUN, PAUL SANG HWA | 1796 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCoya Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Paul Sang Hwa Hyun has the most, with 1 of Coya Therapeutics Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
